Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 691

1.

Molecular epidemiology of HIV-1 infection in immigrant population in northern Italy.

Sagnelli C, Uberti-Foppa C, Bagaglio S, Cella E, Scolamacchia V, Hasson H, Salpietro S, Messina E, Morsica G, Angeletti S, Ciccozzi M, Lazzarin A, Sagnelli E.

Epidemiol Infect. 2020 Feb 5;148:e19. doi: 10.1017/S0950268819002012.

PMID:
32019634
2.
3.

Retrospective Study On The Outcomes Of Two-drugs Regimens Based On Dolutegravir Plus One Reverse Transcriptase Inhibitor In Virologically Suppressed, HIV-Infected Patients.

Galizzi N, Poli A, Galli L, Muccini C, Mastrangelo A, Dell'Acqua R, Maillard M, Bossolasco S, Cinque P, Lazzarin A, Castagna A, Gianotti N.

Int J Antimicrob Agents. 2020 Jan 8:105893. doi: 10.1016/j.ijantimicag.2020.105893. [Epub ahead of print]

PMID:
31926287
4.

A Mobile Application for Exercise Intervention in People Living with HIV.

Bonato M, Turrini F, DE Zan V, Meloni A, Plebani M, Brambilla E, Giordani A, Vitobello C, Caccia R, Piacentini MF, LA Torre A, Lazzarin A, Merati G, Galli L, Cinque P.

Med Sci Sports Exerc. 2020 Feb;52(2):425-433. doi: 10.1249/MSS.0000000000002125.

PMID:
31415448
5.

Viro-immunological outcomes after 13-valent pneumococcal vaccination in HIV-1-infected individuals on stable virological suppression.

Dell'Acqua R, Galli L, Poli A, Mastrangelo A, Guffanti M, Tadini P, Zandona D, Danise A, Gianotti N, Lazzarin A, Castagna A, Nozza S.

AIDS. 2019 Nov 1;33(13):1987-1994. doi: 10.1097/QAD.0000000000002307.

PMID:
31306174
6.

Homeostatic model assessment for insulin resistance index trajectories in HIV-infected patients treated with different first-line antiretroviral regimens.

Gianotti N, Muccini C, Galli L, Poli A, Spagnuolo V, Andolina A, Galizzi N, Ripa M, Messina E, Piatti PM, Lazzarin A, Castagna A.

J Med Virol. 2019 Nov;91(11):1937-1943. doi: 10.1002/jmv.25541. Epub 2019 Jul 16.

PMID:
31286527
7.

Analytical treatment interruption in chronic HIV-1 infection: time and magnitude of viral rebound in adults with 10 years of undetectable viral load and low HIV-DNA (APACHE study).

Castagna A, Muccini C, Galli L, Bigoloni A, Poli A, Spagnuolo V, Nozza S, Racca S, Galli A, Cinque P, Carini E, Lazzarin A.

J Antimicrob Chemother. 2019 Jul 1;74(7):2039-2046. doi: 10.1093/jac/dkz138.

PMID:
31225610
8.

Point-of-care testing for hepatitis C virus infection at an Italian dental clinic: portrait of the pilot study population.

Tecco S, Parisi MR, Gastaldi G, Polizzi E, D'Amicantonio T, Zilocchi I, Gardini I, Gherlone EF, Lazzarin A, Capparè P.

New Microbiol. 2019 Jul;42(3):133-138. Epub 2019 Jun 3.

9.

A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study.

Spagnuolo V, Galli L, Poli A, Bigoloni A, Fumagalli L, Gianotti N, Nozza S, Ferrari D, Locatelli M, Lazzarin A, Castagna A.

Drug Des Devel Ther. 2019 Jan 24;13:477-479. doi: 10.2147/DDDT.S192124. eCollection 2019. No abstract available.

10.

The Management of Geriatric and Frail HIV Patients. A 2017 Update from the Italian Guidelines for the Use of Antiretroviral Agents and the Diagnostic Clinical Management of HIV-1 Infected Persons.

Guaraldi G, Marcotullio S, Maserati R, Gargiulo M, Milic J, Franconi I, Chirianni A, Andreoni M, Galli M, Lazzarin A, D'Arminio Monforte A, Di Perri G, Perno CF, Puoti M, Vella S, Di Biagio A, Maia L, Mussi C, Cesari M, Antinori A.

J Frailty Aging. 2019;8(1):10-16. doi: 10.14283/jfa.2018.42.

PMID:
30734825
11.

Incidence and Predictors of Serological Treatment Response in Early and Late Syphilis Among People Living With HIV.

Spagnuolo V, Poli A, Galli L, Nozza S, Bossolasco S, Cernuschi M, Maillard M, Hasson H, Gianotti N, Guffanti M, Lazzarin A, Castagna A.

Open Forum Infect Dis. 2018 Nov 30;6(1):ofy324. doi: 10.1093/ofid/ofy324. eCollection 2019 Jan.

12.

Evidence-based renewal of the Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons.

Antinori A, Di Biagio A, Marcotullio S, Sarmati L, Andreoni M, Angarano G, Chirianni A, d'Arminio Monforte A, Di Perri G, Galli M, Gianotti N, Girardi E, Gori A, Mussini C, Perno CF, Lazzarin A.

New Microbiol. 2018 Oct;41(4):247-255. Review.

13.

Brief Report: Hyperbilirubinemia Is Associated With a Decreased Risk of Carotid Atherosclerosis in HIV-Infected Patients on Virological Suppression.

Muccini C, Galli L, Poli A, Carbone A, Maillard M, Giusti MC, Spagnuolo V, Bigoloni A, Guffanti M, Gianotti N, Lazzarin A, Castagna A.

J Acquir Immune Defic Syndr. 2018 Dec 15;79(5):617-623. doi: 10.1097/QAI.0000000000001854.

PMID:
30204718
14.

Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen.

Gianotti N, Galli L, Galizzi N, Ripa M, Andolina A, Nozza S, Spagnuolo V, Poli A, Lazzarin A, Castagna A.

Int J Antimicrob Agents. 2018 Oct;52(4):492-499. doi: 10.1016/j.ijantimicag.2018.07.001. Epub 2018 Sep 13.

PMID:
30009958
15.

In vivo evidence that the cannabinoid receptor 2-63 RR variant is associated with the acquisition and/or expansion of HIV infection.

Sagnelli C, Uberti-Foppa C, Hasson H, Bellini G, Minichini C, Salpietro S, Messina E, Barbanotti D, Merli M, Punzo F, Coppola N, Lazzarin A, Sagnelli E, Rossi F.

HIV Med. 2018 Oct;19(9):597-604. doi: 10.1111/hiv.12638. Epub 2018 Jun 22.

PMID:
29932291
16.

Darunavir for the treatment of HIV infection.

Spagnuolo V, Castagna A, Lazzarin A.

Expert Opin Pharmacother. 2018 Jul;19(10):1149-1163. doi: 10.1080/14656566.2018.1484901. Epub 2018 Jun 18. Review.

PMID:
29913082
17.

Managing the long surviving HIV patient: a proposal for a multidimensional first-level diagnostic assessment.

Borderi M, Angarano G, Antinori A, Chirianni A, Cinque P, D'Arminio Monforte A, Di Biagio A, Di Perri G, Galli M, Gori A, Lazzarin A, Mussini C, Perno CF, Quirino T, Rizzardini G, Calza L, Viale P, Acone B, Andreoni M.

New Microbiol. 2018 Apr;41(2):112-117.

18.

Bictegravir.

Spagnuolo V, Castagna A, Lazzarin A.

Curr Opin HIV AIDS. 2018 Jul;13(4):326-333. doi: 10.1097/COH.0000000000000468. Review.

PMID:
29746268
19.

Efficacy and safety of boosted darunavir-based antiretroviral therapy in HIV-1-positive patients: results from a meta-analysis of clinical trials.

Antinori A, Lazzarin A, Uglietti A, Palma M, Mancusi D, Termini R.

Sci Rep. 2018 Mar 27;8(1):5288. doi: 10.1038/s41598-018-23375-6.

20.

Potential associations between atazanavir exposure and clinical outcome: a pharmacokinetic sub-study from the MODAt randomized trial.

Colella E, Cattaneo D, Galli L, Baldelli S, Clementi E, Galli M, Lazzarin A, Castagna A, Rusconi S, Spagnuolo V.

New Microbiol. 2018 Apr;41(2):106-111. Epub 2018 Mar 2.

21.

Long-term efficacy and safety of rilpivirine plus abacavir and lamivudine in HIV-1 infected patients with undetectable viral load.

Galizzi N, Galli L, Poli A, Gianotti N, Carini E, Bigoloni A, Tambussi G, Nozza S, Lazzarin A, Castagna A, Mancusi D, Termini R.

PLoS One. 2018 Feb 16;13(2):e0191300. doi: 10.1371/journal.pone.0191300. eCollection 2018.

22.

Long-term effectiveness of recommended boosted protease inhibitor-based antiretroviral therapy in Europe.

Santos JR, Cozzi-Lepri A, Phillips A, De Wit S, Pedersen C, Reiss P, Blaxhult A, Lazzarin A, Sluzhynska M, Orkin C, Duvivier C, Bogner J, Gargalianos-Kakolyris P, Schmid P, Hassoun G, Khromova I, Beniowski M, Hadziosmanovic V, Sedlacek D, Paredes R, Lundgren JD; EuroSIDA study group.

HIV Med. 2018 May;19(5):324-338. doi: 10.1111/hiv.12581. Epub 2018 Feb 1.

PMID:
29388732
23.

Diagnostic and Prognostic Value of JC Virus DNA in Plasma in Progressive Multifocal Leukoencephalopathy.

Ferretti F, Bestetti A, Yiannoutsos CT, Musick BS, Gerevini S, Passeri L, Bossolasco S, Boschini A, Franciotta D, Lazzarin A, Cinque P.

Clin Infect Dis. 2018 Jun 18;67(1):65-72. doi: 10.1093/cid/ciy030.

PMID:
29346632
24.

Recommendations for the management of pulmonary fungal infections in patients with rheumatoid arthritis.

Galli M, Antinori S, Atzeni F, Meroni L, Riva A, Scirè C, Adorni F, Quartuccio L, Sebastiani M, Airò P, Bazzichi L, Cristini F, Del Bono V, Manfredi A, Viapiana O, De Rosa F, Favalli E, Petrelli E, Salvarani C, Govoni M, Corcione S, Scrivo R, Sarmati L, Lazzarin A, Grassi W, Mastroianni C, Gaeta GB, Ferraccioli G, Cutolo M, De Vita S, Lapadula G, Matucci-Cerinic M, Armignacco O, Sarzi-Puttini P.

Clin Exp Rheumatol. 2017 Nov-Dec;35(6):1018-1028. Epub 2017 Nov 28. Review.

PMID:
29185961
25.

Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients.

Gianotti N, Poli A, Nozza S, Galli L, Galizzi N, Ripa M, Merli M, Carbone A, Spagnuolo V, Lazzarin A, Castagna A.

BMC Infect Dis. 2017 Nov 16;17(1):723. doi: 10.1186/s12879-017-2831-9.

26.

Presence of multiple genotypes in subjects with HPV-16 infection is highly associated with anal squamous intraepithelial lesions in HIV-1 infected males.

Rovelli C, Poli A, Galli L, Cernuschi M, Tamburini AM, Racca S, Tambussi G, Rolla S, Albarello L, Rosati R, Lazzarin A, Castagna A, Nozza S.

PLoS One. 2017 Oct 31;12(10):e0186367. doi: 10.1371/journal.pone.0186367. eCollection 2017.

27.

Long-term efficacy of dolutegravir in treatment-experienced subjects failing therapy with HIV-1 integrase strand inhibitor-resistant virus.

Castagna A, Ferrara M, Galli L, Comi L, Sterrantino G, Cenderello G, Zaccarelli M, Focà E, Roncadori A, Lazzarin A; PRESTIGIO Study Group.

J Antimicrob Chemother. 2018 Jan 1;73(1):177-182. doi: 10.1093/jac/dkx371.

PMID:
29077927
28.

Safety and Efficacy of Ombitasvir, Paritaprevir With Ritonavir ± Dasabuvir With or Without Ribavirin in Patients With Human Immunodeficiency Virus-1 and Hepatitis C Virus Genotype 1 or Genotype 4 Coinfection: TURQUOISE-I Part 2.

Rockstroh JK, Orkin C, Viani RM, Wyles D, Luetkemeyer AF, Lazzarin A, Soto-Malave R, Nelson MR, Bhagani SR, Klinker HHF, Rizzardini G, Girard PM, Tural C, Shulman NS, Mobashery N, Hu YB, Fredrick LM, Pilot-Matias T, Trinh R, Gane E.

Open Forum Infect Dis. 2017 Jul 22;4(3):ofx154. doi: 10.1093/ofid/ofx154. eCollection 2017 Summer.

29.

An observational, retrospective analysis evaluating switching to raltegravir plus abacavir/lamivudine in HIV-1-infected patients: the ORASWIRAL study.

Galli L, Poli A, Muccini C, Galizzi N, Danise A, Spagnuolo V, Gianotti N, Carini E, Lazzarin A, Castagna A.

Infect Dis (Lond). 2018 Mar;50(3):220-222. doi: 10.1080/23744235.2017.1374552. Epub 2017 Sep 11. No abstract available.

PMID:
28891371
30.

Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.

Gallant J, Lazzarin A, Mills A, Orkin C, Podzamczer D, Tebas P, Girard PM, Brar I, Daar ES, Wohl D, Rockstroh J, Wei X, Custodio J, White K, Martin H, Cheng A, Quirk E.

Lancet. 2017 Nov 4;390(10107):2063-2072. doi: 10.1016/S0140-6736(17)32299-7. Epub 2017 Aug 31.

PMID:
28867497
31.

Point-of-care testing for hepatitis C virus infection at alternative and high-risk sites: an Italian pilot study in a dental clinic.

Parisi MR, Tecco S, Gastaldi G, Polizzi E, D'Amicantonio T, Negri S, Gardini I, Schlusnus K, Gherlone E, Capparè P, Lazzarin A.

New Microbiol. 2017 Oct;40(4):242-245. Epub 2017 Aug 21.

32.

Efficacy and safety of switching from branded to generic antiretrovirals in virologically suppressed HIV-infected patients.

Gianotti N, Poli A, Galli L, Franzin M, Tadini P, Galizzi N, Carbone A, Merli M, Muccini C, Oltolini C, Andolina A, Spagnuolo V, Lazzarin A, Castagna A.

PLoS One. 2017 Aug 1;12(8):e0182007. doi: 10.1371/journal.pone.0182007. eCollection 2017.

33.

Cannabinoid receptor 2-63 RR variant is independently associated with severe necroinflammation in HIV/HCV coinfected patients.

Sagnelli C, Uberti-Foppa C, Hasson H, Bellini G, Minichini C, Salpietro S, Messina E, Barbanotti D, Merli M, Punzo F, Coppola N, Lazzarin A, Sagnelli E, Rossi F.

PLoS One. 2017 Jul 31;12(7):e0181890. doi: 10.1371/journal.pone.0181890. eCollection 2017.

34.

Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patients.

Restelli U, Rizzardini G, Antinori A, Lazzarin A, Bonfanti M, Bonfanti P, Croce D.

Ther Clin Risk Manag. 2017 Jun 29;13:787-797. doi: 10.2147/TCRM.S135972. eCollection 2017.

35.

The use of circulating cathodic antigen rapid test and serology for diagnosis of active Schistosoma mansoni infection in migrants in Italy, a non-endemic country: a cross sectional study.

Infurnari L, Galli L, Bigoloni A, Carbone A, Chiappetta S, Sala A, Ceserani N, Lazzarin A, Castagna A, Gaiera/ G.

Mem Inst Oswaldo Cruz. 2017 Jun;112(6):452-455. doi: 10.1590/0074-02760160355.

36.

Simplification to single-tablet regimen of elvitegravir, cobicistat, emtricitabine, tenofovir DF from multi-tablet ritonavir-boosted protease inhibitor plus coformulated emtricitabine and tenofovir DF regimens: week 96 results of STRATEGY-PI.

Arribas JR, DeJesus E, van Lunzen J, Zurawski C, Doroana M, Towner W, Lazzarin A, Nelson M, McColl D, Andreatta K, Swamy R, Szwarcberg J, Nguyen T.

HIV Clin Trials. 2017 May;18(3):118-125. doi: 10.1080/15284336.2017.1330440. Epub 2017 May 30. Erratum in: HIV Clin Trials. 2018 Aug;19(4):163.

PMID:
28555519
37.

Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2016.

Antinori A, Di Biagio A, Marcotullio S, Andreoni M, Chirianni A, d'Arminio Monforte A, Galli M, Mazzotta F, Mussini C, Puoti M, Lazzarin A; Italian HIV Guidelines Working Group.

New Microbiol. 2017 Apr;40(2):86-98.

38.

NS3 protease resistance-associated substitutions in liver tissue and plasma samples from patients infected by hepatitis C virus genotype 1A or 1B.

Morsica G, Andolina A, Merli M, Messina E, Hasson H, Lazzarin A, Uberti-Foppa C, Bagaglio S.

Arch Virol. 2017 Aug;162(8):2271-2277. doi: 10.1007/s00705-017-3341-1. Epub 2017 Apr 18.

PMID:
28421367
39.

Occurrence of hepatocellular carcinoma in HIV/HCV co-infected patients treated with direct-acting antivirals.

Hasson H, Merli M, Messina E, Bhoori S, Salpietro S, Morsica G, Regalia E, Bagaglio S, Lazzarin A, Uberti-Foppa C, Mazzaferro V.

J Hepatol. 2017 Aug;67(2):415-417. doi: 10.1016/j.jhep.2017.03.032. Epub 2017 Apr 12. No abstract available.

PMID:
28411040
40.

Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection-authors' response.

Nozza S, Poli A, Ripa M, Galli L, Chiappetta S, Spagnuolo V, Rovelli C, Lazzarin A, Castagna A, Tambussi G.

J Antimicrob Chemother. 2017 May 1;72(5):1549-1550. doi: 10.1093/jac/dkx073. No abstract available.

PMID:
28333303
41.

Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a randomized, double-blind, active-controlled phase 3 trial<sup/>.

Post FA, Yazdanpanah Y, Schembri G, Lazzarin A, Reynes J, Maggiolo F, Yan M, Abram ME, Tran-Muchowski C, Cheng A, Rhee MS.

HIV Clin Trials. 2017 May;18(3):135-140. doi: 10.1080/15284336.2017.1291867. Epub 2017 Mar 17.

PMID:
28303753
42.

Safety and Efficacy of Pegylated Interferon Lambda, Ribavirin, and Daclatasvir in HCV and HIV-Coinfected Patients.

Nelson M, Rubio R, Lazzarin A, Romanova S, Luetkemeyer A, Conway B, Molina JM, Xu D, Srinivasan S, Portsmouth S.

J Interferon Cytokine Res. 2017 Mar;37(3):103-111. doi: 10.1089/jir.2016.0082. Epub 2017 Feb 17.

PMID:
28282271
43.

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study.

Orkin C, DeJesus E, Ramgopal M, Crofoot G, Ruane P, LaMarca A, Mills A, Vandercam B, de Wet J, Rockstroh J, Lazzarin A, Rijnders B, Podzamczer D, Thalme A, Stoeckle M, Porter D, Liu HC, Cheng A, Quirk E, SenGupta D, Cao H.

Lancet HIV. 2017 May;4(5):e195-e204. doi: 10.1016/S2352-3018(17)30031-0. Epub 2017 Mar 2.

PMID:
28259777
44.

Generic antiretrovirals for the treatment of HIV: a novel challenge for Western countries?
.

Cattaneo D, Andreoni M, Carosi G, Cauda R, Lazzarin A, Rizzardini G.

Int J Clin Pharmacol Ther. 2017 May;55(5):381-393. doi: 10.5414/CP202775. Review.

PMID:
28211784
45.

Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study.

Sulkowski MS, Fessel WJ, Lazzarin A, Berenguer J, Zakharova N, Cheinquer H, Côté P, Dieterich D, Gadano A, Matthews G, Molina JM, Moreno C, Pineda JA, Pulido F, Rivero A, Rockstroh J, Hernandez D, McPhee F, Eley T, Liu Z, Mendez P, Hughes E, Noviello S, Ackerman P.

Hepatol Int. 2017 Mar;11(2):188-198. doi: 10.1007/s12072-017-9788-z. Epub 2017 Feb 16.

PMID:
28210927
46.

A pilot study of brisk walking in sedentary combination antiretroviral treatement (cART)- treated patients: benefit on soluble and cell inflammatory markers.

Bonato M, Galli L, Passeri L, Longo V, Pavei G, Bossolasco S, Bertocchi C, Cernuschi M, Balconi G, Merati G, Lazzarin A, La Torre A, Cinque P.

BMC Infect Dis. 2017 Jan 11;17(1):61. doi: 10.1186/s12879-016-2095-9.

47.

Dynamic change in the NS3 protease domain in HIV/HCV-coinfected patients naïve to anti-HCV protease inhibitors.

Bagaglio S, Messina E, Hasson H, Merli M, Andolina A, Lazzarin A, Uberti-Foppa C, Morsica G.

New Microbiol. 2017 Jan;40(1):53-55. Epub 2017 Jan 5.

48.

Associations of statins and antiretroviral drugs with the onset of type 2 diabetes among HIV-1-infected patients.

Spagnuolo V, Galli L, Poli A, Salpietro S, Gianotti N, Piatti P, Cossarini F, Vinci C, Carini E, Lazzarin A, Castagna A.

BMC Infect Dis. 2017 Jan 7;17(1):43. doi: 10.1186/s12879-016-2099-5.

49.

HIV Clinical Pathway: A New Approach to Combine Guidelines and Sustainability of Anti-Retroviral Treatment in Italy.

Croce D, Lazzarin A, Rizzardini G, Gianotti N, Scolari F, Foglia E, Garagiola E, Ricci E, Bini T, Quirino T, Viganò P, Re T, D'Arminio Monforte A, Bonfanti P.

PLoS One. 2016 Dec 28;11(12):e0168399. doi: 10.1371/journal.pone.0168399. eCollection 2016.

50.

Supplemental Content

Loading ...
Support Center